Society of Hematologic Oncology Insider news

SOHO Insider
  • 5.0 (1)
  • Life Sciences
  • Updated Biweekly

SOHO Insider delivers on the latest news in hematologic oncology and updates from the Society of Hematologic Oncology

  1. May 7

    Dr. Nirav Shah on the next iteration in CAR-T cell therapy in blood cancer

    In this SOHO Insider podcast, host Megan Melody, MD, from Tampa General Hospital, spoke with Nirav Shah, MD, professor at the Medical College of Wisconsin, on news from the 2026 Tandem Meetings, including updates on dual-targeted CAR T-cell results in CLL and interim phase 2 data on zamtocabtagene autoleucel (zamto-cel) in in transplant-ineligible patients with DLBCL. Of dual-targeting CAR-T cell therapies, he said, “I think this is the next iteration in CAR. Zamtocabtagene is one of four 20/19 CARs under development and if you look at the data for all of them, they look to be highly efficacious, better than our standard CD19-CAR.” Listen to more podcasts on sohoinsider.com.

    15 min

  2. Mar 31

    Dr. Tara Graff presents Implementing bispecific antibodies in community practice

    The second session of the Community Oncology Brown Bag Series, hosted by SOHO Insider, held on February 11, 2026, and featured guest speaker Tara Graff, DO, MS, at Mission Cancer + Blood and director of their clinical research program. Dr. Graff discussed “Moving CAR T-cell therapies into the community setting.” This program is led by Loretta Nastoupil, MD, the SOHO Insider community oncology section editor. To register for the series, go to https://soho.click/community-oncology-series

    27 min

  3. Mar 17

    Dr. Iacoboni on improving CAR T-cell therapy outcomes in lymphoma

    Gloria Iacoboni, MD, PhD, a hematologist at Vall d’Hebron University Hospital in Barcelona, Spain, spoke with Dr. James Day, a clinical research training fellow at UCL in London, during this SOHO Insider podcast episode recorded at the inaugural SOHO UK 2026 meeting. The meeting was held in London March 3 and 4 at the Royal College of Physicians in London.   Dr. Iacoboni discussed strategies to improve outcomes in high-grade lymphoma, focusing on improved patient selection, the emergence of dual-targeted CAR T-cell products (CD19/CD20), and how circadian rhythms might impact infusion efficacy.  Follow more news from SOHO UK.

    14 min

  4. Mar 10

    Why clinicians should lead hospitals, according to Prof. Amanda Goodall

    Prof. Amanda Goodall, director of the Executive Master’s in Medical Leadership (EMML), a specialized MSc degree from Bayes Business School offering advanced leadership training to medical doctors, joined SOHO Insider podcast host Prof. Christopher Fox, a professor of hematology at Nottingham University Hospitals NHS Trust, for a discussion on expert leadership in healthcare. According to Prof. Goodall, expert leadership is the idea that organizations perform best when leaders are experts in the core work of the institution. As part of this work, she runs an executive master’s program in medical leadership, designed to help physicians develop the skills needed to lead healthcare organizations while maintaining credibility as clinicians. Her research argues that in healthcare this means placing experienced, high-performing physicians in leadership roles rather than relying primarily on generalist managers. Many doctors, she noted, are interested in leadership because they want to drive meaningful change and improve patient care, but historically they have had limited access to formal leadership training. The podcast was taped during the inaugural meeting of SOHO UK, where Prof. Goodall gave a talk after dinner on the topic. Learn about the Executive Master’s in Medical Leadership (EMML) program.

    6 min

  5. Feb 27

    Prof. Cwynarski previews CNS, peripheral T-cell lymphoma sessions ahead of SOHO UK

    Prof. Kate Cwynarski, MD, PhD, joined SOHO Insider podcast host Megan Melody, MD, for a discussion previewing lymphoma sessions she will lead at the inaugural SOHO UK meeting, scheduled for March 3–4, 2026, in London. Prof. Cwynarski will chair a “Meet the Expert” roundtable on challenges and controversies in managing central nervous system (CNS) lymphoma. The session will include a seven-year update of the MARIETTA study, which examined treatment strategies for secondary CNS lymphoma, as well as findings from a large real-world evidence study of secondary CNS lymphoma. She will also lead a session on peripheral T-cell lymphoma focused on the shift toward biologically informed therapy. The presentation will highlight the TERZO study and explore how emerging biologic insights may guide treatment decisions in this heterogeneous group of lymphomas. The sessions are part of the program for the first SOHO UK meeting, which will bring together global clinicians and researchers to discuss advances in the treatment of blood cancers.

    12 min

  6. Feb 9

    Public-private partnerships needed to sustain progress in blood cancer treatment

    John DiPersio, MD, PhD, current president of SOHO and director of the Center for Gene and Cellular Immunotherapy at Washington University School of Medicine in St. Louis, Missouri, discusses the need for public-private partnerships to move novel therapies forward in the treatment of blood cancers. He also speaks about how cross-sector collaboration can create better research paths for the future. For SOHO 2026, Dr. DiPersio chose the theme “Advancing care through collaborative science,” a timely topic as NIH funding continues to decline. “SOHO 2026 will explore how public-private partnerships can sustain discovery, preserve basic research, and ensure access to innovation for patients around the world,” Dr. DiPersio said in a recent interview with SOHO Insider. Register for SOHO 2026 today Register today for SOHO 2026 at soho.click/2026. SOHO members receive a 40% discount. Join SOHO for free at http://soho.click/join.

    4 min

  7. Jan 30

    Drs. Melody, Phillips talk glofitamab in MCL

    In this podcast episode recorded at the Thirteenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2025), Megan Melody, MD, from Tampa General Hospital, spoke with Tycel J. Phillips, MD, from the City of Hope Cancer Center, on the latest advancements in mantle cell lymphoma (MCL), including the phase 1/2 trial in relapsed or refractory MCL recently published in the Journal of Clinical Oncology. In the trial led by Dr. Phillips, the investigators evaluated glofitamab monotherapy in patients with relapsed or refractory B-cell lymphomas, with obinutuzumab pretreatment to mitigate the risk of cytokine release syndrome with glofitamab. Dr. Phillips also spoke about treating patients with relapsed or refractory non-Hodgkin lymphoma with venetoclax. Listen to other podcast episodes of SOHO Insider.

    8 min

  8. Jan 16

    Advances in essential thrombocythemia with Drs. Kuykendall, Tremblay

    In this episode of the SOHO Insider podcast, Andrew Kuykendall, MD, assistant member at Moffitt Cancer Center, and Douglas Tremblay, MD, assistant professor of medicine at Icahn School of Medicine at Mount Sinai, discuss how to approach the treatment of essential thrombocythemia. “The first thing I do whenever a patient walks into the clinic with ET is think about their risk status,” Dr. Tremblay said. “When we speak about risk status, what we’re really speaking about is risk of thrombosis. There’s several different risk stratification methods, but they all rely on three clinical factors in general, which is age of prior thrombosis, which is probably the most potent risk factor.” This episode also includes a discussion on the SURPASS-ET trial, which showed ropeginterferon alfa-2b outperformed anagrelide for disease control. Plus, a look into how new CALR-targeted antibodies improve bone marrow in early studies.   Dr. Masarova discusses SURPASS-ET study at EHA 2025

    17 min
See All (16)

About

SOHO Insider delivers on the latest news in hematologic oncology and updates from the Society of Hematologic Oncology

Information

You Might Also Like